<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282995</url>
  </required_header>
  <id_info>
    <org_study_id>FDFDR</org_study_id>
    <nct_id>NCT02282995</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Association With Functional Dyspepsia and Mood Disorders</brief_title>
  <acronym>FDFDR</acronym>
  <official_title>Effect of Genetic Association With Functional Dyspepsia and Mood Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Functional dyspepsia (FD) is one of the commonest digestive disorders. The pathophysiology of&#xD;
      functional dyspepsia is uncertain. Risk factors include genetics, gender, age, helicobacter&#xD;
      pylori infection, etc. However, few reported the association of genetic contribution to the&#xD;
      development of FD and mood disorder.&#xD;
&#xD;
      Indication:&#xD;
&#xD;
      Functional dyspepsia patients&#xD;
&#xD;
      Study center(s):&#xD;
&#xD;
      Prince of Wales Hospital, Hong Kong&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        -  To evaluate genetic factors on development of functional dyspepsia &amp; common mood&#xD;
           disorders&#xD;
&#xD;
        -  To evaluate genetic factors on the severity of function dyspepsia &amp; mood disorders&#xD;
&#xD;
        -  To develop a diagnostic test for classification of functional dyspepsia by plasma&#xD;
           ghrelin and serotonin expression&#xD;
&#xD;
        -  To collect sleep data for future use&#xD;
&#xD;
        -  To save blood sample for future retrospective diagnostic or genetic examination&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Case-control cross sectional study&#xD;
&#xD;
      Number of subjects:&#xD;
&#xD;
      Total of 1200 subjects (300 FD patients + 300 relatives of FD patients FDR) and (300 Controls&#xD;
      + 300 FDR)&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
      Functional dyspepsia patients age 18-60&#xD;
&#xD;
      Duration of study:&#xD;
&#xD;
      1 May 2012 - 30 April 2013&#xD;
&#xD;
      Primary variable(s):&#xD;
&#xD;
      Genetic polymorphisms of targeted genes, plasma ghrelin and serotonin expression&#xD;
&#xD;
      Secondary variable(s):&#xD;
&#xD;
      FD global symptom assessment and symptom scores&#xD;
&#xD;
      Number of visits: 1&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        -  Shared genetic factors contribute to the development of FD and common psychological&#xD;
           disorders&#xD;
&#xD;
        -  FD patients contribute to suppression of plasma ghrelin and serotonin expression&#xD;
           compared to healthy controls&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:&#xD;
&#xD;
      All subjects will participate in (1) Demographic assessment, (2) Questionnaires&#xD;
      administration and (3) Blood sample collection. The three steps must be completed within 2&#xD;
      weeks.&#xD;
&#xD;
        1. Demographic assessment&#xD;
&#xD;
             -  Demographic: age, gender&#xD;
&#xD;
             -  Anthropometric measurements: body mass index, height, weight&#xD;
&#xD;
             -  Smoke and drink habit&#xD;
&#xD;
             -  Comorbidity and medical history&#xD;
&#xD;
        2. Questionnaires administration&#xD;
&#xD;
             -  A combined functional gastrointestinal (GI) symptom questionnaire (FGISQ) based on&#xD;
                recall of the past 7 days will be used for assessment all GI symptoms including&#xD;
                regurgitation, heartburn, epigastric pain, postprandial fullness, abdominal pain,&#xD;
                diarrhea, constipation etc. All questions use a 4-point (0-3) Likert scale.&#xD;
&#xD;
             -  FGI Screening Questionnaire (v.3, 20101011) for screening of functional&#xD;
                gastrointestinal disorder according to Rome III criteria. The questionnaire&#xD;
                incorporate a GERD diagnostic questionnaire GERDQ (Chinese version)&#xD;
&#xD;
             -  Hospital Anxiety and Depression Scale (HADS) for a self administered scale for&#xD;
                seven covering depression and seven covering anxiety.&#xD;
&#xD;
             -  Psychological disorder: Patient Health Questionnaire (PHQ) will be used for&#xD;
                screening of concomitant psychological disorder such as depression and generalized&#xD;
                anxiety disorder.&#xD;
&#xD;
             -  The Epworth Sleepiness Scale, Pittsburgh sleep quality index, and General Sleep&#xD;
                Quality Questionnaire to collect sleep data for future use.&#xD;
&#xD;
        3. Blood sample collection&#xD;
&#xD;
             -  Up to 20 ml of fasting blood sample will be collected for study aims 1-4.&#xD;
&#xD;
             -  Fasting glucose test will be performed for FD patients&#xD;
&#xD;
             -  Serology test of Hp status will be performed for healthy volunteers and all FDRs&#xD;
&#xD;
      Subjects who had fasting glucose test or serology test performed within one year before study&#xD;
      enrollment can be exempted from repeating the tests if they refuse to repeat the tests. In&#xD;
      such cases, their previous test results will be recorded and used in this study.&#xD;
&#xD;
      If the subjects are found to be positive as a result of Helicobacter pylori (Hp) serology&#xD;
      test, a referral letter with prescription suggestion will be given to the subjects to seek&#xD;
      proper medical care in the primary care setting. In current practice, Hp eradication is not&#xD;
      mandatory for asymptomatic subjects.&#xD;
&#xD;
      Laboratory work:&#xD;
&#xD;
      Nine ml of blood will be used for the detection of biomarkers for functional dyspepsia&#xD;
      through single nucleotide polymorphism (SNPs). The genotyping DNA will be isolated from whole&#xD;
      blood samples by (FlexGene DNA kit, Qiagen). High-throughput genotyping will be performed on&#xD;
      the serotonin 3A receptor polymorphism (rs1062613) and ghrelin CLOCK 3111C polymorphism&#xD;
      (rs1801260). It will be analyzed by Applied Biosystems (ABI) 3730xl DNA Analyzer.&#xD;
&#xD;
      Six ml of blood will be used for detection of plasma ghrelin and serotonin expression for&#xD;
      development of diagnostic test in classification of functional dyspepsia by ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences of genetic polymorphism in targeted genes in patients with FD and mood disorders</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Differences of genetic polymorphism in targeted genes in patients with FD and mood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of psychiatric disorder with PHQ and HADS</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Diagnosis of psychiatric disorder with PHQ and HADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences of plasma ghrelin and serotonin expression in FD patients and study controls.</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Differences of plasma ghrelin and serotonin expression in FD patients and study controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Symptom scores</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>•FDR-Relatives of FD patients</arm_group_label>
    <description>Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.&#xD;
Up to 20 ml of fasting blood sample will be collected&#xD;
Serology test of Hp status will be performed for healthy volunteers and all FDRs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>•FDC-Healthy control</arm_group_label>
    <description>Healthy control. Controls who are self-referred to this study will be recruited.&#xD;
Up to 20 ml of fasting blood sample will be collected&#xD;
Fasting glucose test will be performed for FD patients&#xD;
Serology test of Hp status will be performed for healthy volunteers and all FDRs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>•FD-Patients with FD</arm_group_label>
    <description>Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.&#xD;
Up to 20 ml of fasting blood sample will be collected&#xD;
Fasting glucose test will be performed for FD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>•FDCR-Relatives of healthy controls</arm_group_label>
    <description>Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.&#xD;
Up to 20 ml of fasting blood sample will be collected&#xD;
Serology test of Hp status will be performed for healthy volunteers and all FDRs</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nine ml of blood will be used for the detection of biomarkers for functional dyspepsia&#xD;
      through single nucleotide polymorphism (SNPs). The genotyping DNA will be isolated from whole&#xD;
      blood samples by (FlexGene DNA kit, Qiagen). High-throughput genotyping will be performed on&#xD;
      the serotonin 3A receptor polymorphism (rs1062613) and ghrelin CLOCK 3111C polymorphism&#xD;
      (rs1801260). It will be analyzed by Applied Biosystems (ABI) 3730xl DNA Analyzer.&#xD;
&#xD;
      Six ml of blood will be used for detection of plasma ghrelin and serotonin expression by&#xD;
      ELISA.&#xD;
&#xD;
      The remaining blood samples will be stored in the Laboratory of Institute of Digestive&#xD;
      Diseases for tests stated in the Aim section, also for future studies for emerging diseases&#xD;
      related to FGID.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms&#xD;
        suggestive of FGID or who participated in PI's previous clinical trials will be invited to&#xD;
        participate in this study as FD patients.&#xD;
&#xD;
        Patients not suffering from FGID will be identified from the gastrointestinal specialty&#xD;
        clinic or Endoscopy Center, Prince of Wales Hospital as healthy volunteers. These patients&#xD;
        may include those referred for GI malignancy screening.&#xD;
&#xD;
        Study advertisement will be posted in public area of Prince of Wales Hospital, and on the&#xD;
        educational website (www.digestion.hk) which is maintained by PI. Controls who are&#xD;
        self-referred to this study will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subject&#xD;
&#xD;
               -  Age 18-60&#xD;
&#xD;
               -  Provision of written consent&#xD;
&#xD;
        Additional to FD patient&#xD;
&#xD;
          -  Symptoms fulfilling Rome III criteria of functional dyspepsia&#xD;
&#xD;
          -  Negative upper endoscopy (oesophagogastroduodenoscopy or OGD) finding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All subject&#xD;
&#xD;
               -  History of cancer&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  History of gastric surgery&#xD;
&#xD;
               -  Acid suppressants or medications that affect motility in past 4 weeks&#xD;
&#xD;
               -  Organic disease as cause of dyspepsia (for subjects with dyspeptic symptom)&#xD;
&#xD;
        Additional to healthy volunteer&#xD;
&#xD;
        • Any gastrointestinal symptoms (including acid regurgitation, heartburn, epigastric pain,&#xD;
        bloating sensation, constipation, abdominal pain, diarrhea) in the past 4 weeks&#xD;
&#xD;
        Additional to FD patient&#xD;
&#xD;
          -  Frequent (once or more per week) acid reflux or heartburn symptoms&#xD;
&#xD;
          -  Helicobacter pylori (Hp) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin C.Y. Wu, MBChB(CUHK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin C.Y. Wu, MBChB(CUHK)</last_name>
    <phone>(852)35053476</phone>
    <email>justinwu@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kay Yuen, M Phil</last_name>
    <phone>(852)35053476</phone>
    <email>kayyuen@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin C.Y. Wu, MBChB(CUHK)</last_name>
      <phone>(852)35053476</phone>
      <email>justinwu@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Justin C.Y. Wu, MBChB(CUHK)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>http://www.cuhk.edu.hk</url>
    <description>The Chinese University of Hong Kong</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Justin Che-Yuen Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Functional dyspepsia</keyword>
  <keyword>symptom response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

